6 citations
,
November 2022 in “Journal of autoimmunity” This case report discusses a successful treatment of Alopecia Areata with tofacitinib and includes a literature review on the condition's pathophysiology and the mechanism of JAK inhibitors, though it notes the high failure rate of available treatments and absence of FDA-approved options.
October 2022 in “Journal of Armed Forces Medical College, Bangladesh” In this clinical trial, Tofacitinib effectively promoted hair regrowth in patients with alopecia areata, alopecia totalis, and alopecia universalis, with 75.6% experiencing no side effects, making it a promising treatment option according to the study.
39 citations
,
April 2016 in “Case Reports in Dermatology” This study observed initial hair regrowth in a businessman with alopecia areata universalis treated with tofacitinib, but the effect diminished, leading to renewed hair loss.
5 citations
,
June 2015 in “Veterinary dermatology” This case report describes a canine with alopecia areata universalis treated with oral ciclosporin, which was associated with hair regrowth, but some areas remained hairless after 17 months.
45 citations
,
July 2008 in “International Journal of Dermatology” This study found that oral sulfasalazine led to varying hair regrowth outcomes in patients with persistent alopecia areata, with 56.3% showing moderate to good responses.
39 citations
,
April 2003 in “Australasian journal of dermatology” This study found that PUVA treatment resulted in complete hair regrowth in over half of patients with alopecia areata totalis or universalis, despite a higher treatment failure rate in those with a family history of the condition.
62 citations
,
April 2002 in “Journal of the American Academy of Dermatology” In this study, sulfasalazine treatment resulted in cosmetically acceptable hair regrowth in 23% of patients with severe alopecia areata in whom a response could be determined.
